Miki Sakamoto
Papers
1
Total Citations
4
H-Index
1
About
Miki Sakamoto is a leading urologic oncologist whose research focuses on optimizing surgical outcomes for prostate cancer, particularly through robotic-assisted radical prostatectomy. Her most cited work critically examines the therapeutic value of extended pelvic lymph node dissection (ePLND) in intermediate- to high-risk prostate cancer patients. In a landmark 2025 study, Sakamoto and her team demonstrated that ePLND may not provide a significant biochemical recurrence benefit, challenging long-held surgical conventions and prompting a shift toward more selective, morbidity-sparing approaches. This contribution, already garnering 4 citations shortly after publication, underscores her impact on evidence-based urologic surgery. Beyond this, Sakamoto is recognized for advancing minimally invasive techniques and refining risk stratification to personalize treatment. Her work bridges the gap between aggressive oncologic control and quality of life, making her a key voice in contemporary prostate cancer management. For students and researchers, Sakamoto’s research exemplifies how rigorous clinical investigation can reshape standard practice, emphasizing the importance of questioning dogma to improve patient outcomes.
Research Focus
Key Achievements
Top Papers
- 1